Search Results

You are looking at 61 - 70 of 1,455 items for :

  • Refine by Access: All x
Clear All
Full access

Changes in Management of Left-Sided Obstructive Colon Cancer: National Practice and Guideline Implementation

Joyce Valerie Veld, Femke Julie Amelung, Wernard Aat Antoine Borstlap, Emo Eise van Halsema, Esther Catharina Josephina Consten, Peter Derk Siersema, Frank ter Borg, Edwin Silvester van der Zaag, Paul Fockens, Willem Adrianus Bemelman, Jeanin Elise van Hooft, Pieter Job Tanis, and for the Dutch Snapshot Research Group

postoperative morbidity and mortality. 1 Initial decompression of a distended colon as a bridge to surgery (BTS) is likely to change the risk profile of the patient, but it requires an additional intervention with its own disadvantages. The construction of a

Full access

Esophageal and Esophagogastric Junction Cancers

Jaffer A. Ajani, James S. Barthel, David J. Bentrem, Thomas A. D'Amico, Prajnan Das, Crystal S. Denlinger, Charles S. Fuchs, Hans Gerdes, Robert E. Glasgow, James A. Hayman, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, A. Craig Lockhart, Mary F. Mulcahy, Mark B. Orringer, Raymond U. Osarogiagbon, James A. Posey, Aaron R. Sasson, Walter J. Scott, Stephen Shibata, Vivian E. M. Strong, Thomas K. Varghese Jr., Graham Warren, Mary Kay Washington, Christopher Willett, and Cameron D. Wright

surgical specimen in patients who had surgery as primary therapy. The revised 2010 AJCC staging classification (available online, in these guidelines, at [ST-1]) is based on the risk-adjusted random forest analysis of the data generated by

Full access

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Joyce Liu, Haider Mahdi, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

Overview Primary treatment of presumed ovarian, fallopian tube, or primary peritoneal cancer usually consists of appropriate surgical staging and debulking surgery, followed in most (but not all) patients by systemic chemotherapy (OV-1, OV-4, above

Full access

Epithelial Ovarian Cancer

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner

and fallopian tube cancer; however, these high-risk women have a residual risk for primary peritoneal cancer after prophylactic salpingo-oophorectomy. 6 , 7 The risks of surgery include injury to the bowel, bladder, ureter, and vessels. 8 Recent data

Full access

Head and Neck Cancers

David G. Pfister, Kie-Kian Ang, David M. Brizel, Barbara A. Burtness, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr., Ying J. Hitchcock, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Sandeep Samant, Giuseppe Sanguineti, David E. Schuller, Jatin P. Shah, Sharon Spencer, Andy Trotti III, Randal S. Weber, Gregory T. Wolf, and Frank Worden

. For example, some tumors deemed unresectable are in fact anatomically resectable, but surgery is not pursued because of medical contraindications to surgery or because surgery is not anticipated to improve prognosis (see Resectable Versus Unresectable

Full access

Uterine Neoplasms

Benjamin E. Greer, Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Patricia J. Eifel, Warner K. Huh, Wainwright Jaggernauth, Daniel S. Kapp, John J. Kavanagh, John R. Lurain III, Mark Morgan, Robert J. Morgan Jr, C. Bethan Powell, Steven W. Remmenga, R. Kevin Reynolds, Angeles Alvarez Secord, William Small Jr, and Nelson Teng

stage IIIC endometrial cancer . Gynecol Oncol 2005 ; 99 : 689 – 695 . 26 Creutzberg CL van Putten WL Koper PC . Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre

Full access

Patient Navigation for Timely, Guideline-Adherent Adjuvant Therapy for Head and Neck Cancer: A National Landscape Analysis

Evan M. Graboyes, Michelle Chappell, Kelsey A. Duckett, Katherine Sterba, Chanita Hughes Halbert, Elizabeth G. Hill, Bhishamjit Chera, Jessica McCay, Sidharth V. Puram, Salma Ramadan, Vlad C. Sandulache, Russel Kahmke, Brian Nussenbaum, Anthony J. Alberg, Electra D. Paskett, and Elizabeth Calhoun

Background In 2021, the American College of Surgeons Commission on Cancer (CoC) approved the initiation of postoperative radiation therapy (PORT) within 6 weeks of surgery for head and neck cancer (HNC) as its first and only HNC quality metric

Full access

Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer

Joseph M. Herman, John P. Hoffman, Sarah P. Thayer, and Robert A. Wolff

limited metastatic burden of disease. Role of Surgical Management in Metastatic PCA A small number of studies have identified that surgery can have a statistically significant survival advantage in selected patients with minimal metastatic disease

Full access

Massachusetts General Hospital: Improving Patient Access to the Breast Oncology Clinic

Inga T. Lennes, Mara Bloom, Nie Bohlen, and Beverly Moy

more than 12 weeks from last definitive surgery ( Figure 1 ). As might be expected, failing to reach the target of chemotherapy sooner than 12 weeks from surgery was more commonly seen in patients who underwent initial surgery outside of the MGH Cancer

Full access

CLO20-055: Optimal Timing of Radical Surgery From Diagnosis in Muscle Invasive Bladder Cancer (MIBC)

Saurabh Parasramka, Quan Chen, Bin Huang, Peng Wang, and Zin Myint

Background: Non-metastatic muscle invasive bladder cancer (MIBC) is treated with radical cystectomy and survival is closely associated with final pathologic staging. For patients undergoing primary surgery there is evidence that delay > 90 days